Monte Rosa Therapeutics Files 8-K on Financials

Ticker: GLUE · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1826457

Monte Rosa Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyMonte Rosa Therapeutics, Inc. (GLUE)
Form Type8-K
Filed DateJan 10, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $377.0 million, $150 million
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, sec-filing

Related Tickers: MRSA

TL;DR

Monte Rosa (MRSA) filed an 8-K on Jan 10, 2025, covering financial condition and operations. Details TBD.

AI Summary

On January 10, 2025, Monte Rosa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or operational updates were detailed in the provided excerpt.

Why It Matters

This filing indicates that Monte Rosa Therapeutics is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor the company's health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting financial condition and operations, with no immediate negative or positive news indicated in the provided text.

Key Players & Entities

  • Monte Rosa Therapeutics, Inc. (company) — Registrant
  • January 10, 2025 (date) — Date of earliest event reported
  • 001-40522 (other) — SEC File Number
  • 321 Harrison Avenue, Suite 900 Boston, MA 02118 (address) — Principal executive offices

FAQ

What specific financial information is being reported in this 8-K?

The provided excerpt states the 8-K covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific figures within the excerpt.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 10, 2025.

What is the SEC file number for Monte Rosa Therapeutics?

The SEC file number for Monte Rosa Therapeutics is 001-40522.

Where are Monte Rosa Therapeutics' principal executive offices located?

Monte Rosa Therapeutics' principal executive offices are located at 321 Harrison Avenue, Suite 900, Boston, MA 02118.

What is the Standard Industrial Classification code for Monte Rosa Therapeutics?

The Standard Industrial Classification code for Monte Rosa Therapeutics is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 950 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-01-10 07:03:24

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GLUE The Nasdaq
  • $377.0 million — arketable securities are expected to be $377.0 million as of December 31, 2024, including the
  • $150 million — 024, including the previously announced $150 million upfront payment from Novartis. The pr

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition On January 10, 2025, Monte Rosa Therapeutics, Inc. (the "Company") released the following preliminary information about its cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024. The Company's preliminary estimated cash, cash equivalents, restricted cash, and marketable securities are expected to be $377.0 million as of December 31, 2024, including the previously announced $150 million upfront payment from Novartis. The preliminary estimate of cash and cash equivalents reflect management's current views and may change as a result of management's review of results and other factors, including a wide variety of significant business, economic and competitive risks and uncertainties. Such preliminary financial information is subject to the finalization and closing of the accounting books and records of the Company (which have yet to be performed) and should not be viewed as a substitute for full audited financial statements prepared in accordance with U.S. GAAP. In the course of preparing and finalizing the financial statements for the year ended December 31, 2024, the preliminary estimates of cash and cash equivalents for the year ended December 31, 2024 will be subject to change and the Company may identify items that will require it to make adjustments to its preliminary estimates of its cash and cash equivalents. Any such changes could be material. For these or other reasons, the preliminary estimates of the Company cash and cash equivalents for the year ended December 31, 2024 may not ultimately be indicative of its results for such period and actual results may differ materially. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to these preliminary estimated results, nor have they expressed any opinion or any other form of assurance on these preliminary estimated results. The inform

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On January 10, 2025, the Company issued a press release titled "Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025". The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On January 10, 2025, the Company issued a corporate presentation to provide a corporate update in conjunction with its participation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release issued by Monte Rosa Therapeutics, Inc. dated January 10, 2025. 99.2 Corporate Presentation furnished by Monte Rosa Therapeutics, Inc. on January 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monte Rosa Therapeutics, Inc. Date: January 10, 2025 By: /s/ Markus Warmuth Markus Warmuth President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.